In Brief: Medical device reporting
This article was originally published in The Gray Sheet
Executive SummaryMedical device reporting: FDA stays effective date of certain portions of the annual baseline reporting requirement of the agency's December 1995 final manufacturer MDR rule. The stay, published in the July 31 Federal Register, applies to the number of devices manufactured, distributed or in use (so-called "denominator data"), which FDA had intended to use in determining the prevalence of adverse events. The agency is issuing the stay "until further notice" in response to device industry concerns about the provision. FDA will explore mechanisms for obtaining denominator data via a small-scale pilot project slated to begin this fall ("The Gray Sheet" July 15, p. 10). The remaining portions of the MDR rule became effective as scheduled July 31...
You may also be interested in...
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.
HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.